Duty to recontact in genomic cancer care: A tool helping to assess the professional's responsibility

Martine C. Ploem; Noor A.A. Giesbertz; Annelien L. Bredenoord; Valesca P. Retèl; Wim H. van Harten

doi:10.1016/j.ejca.2023.03.004

Duty to recontact in genomic cancer care: A tool helping to assess the professional's responsibility

Martine C. Ploem
, Noor A.A. Giesbertz
, Annelien L. Bredenoord
, Valesca P. Retèl^*
, Wim H. van Harten

^*Corresponding author for this work

Amsterdam UMC
University of Amsterdam
Utrecht University
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
University of Twente
University Medical Centre Utrecht

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

188 Downloads (Pure)

Abstract

Tumour DNA and germline testing, based on DNA-wide sequencing analysis, are becoming more and more routine in clinical-oncology practice. A promising step in medicine, but at the same time leading to challenging ethicolegal questions. An important one is under what conditions individuals (patients and their relatives, research participants) should be recontacted with new information, even if many years have passed since the last contact. Based on legal- and ethical study, we developed a tool to help professionals to decide whether or not to recontact an individual in specific cases. It is based on four assessment criteria: (1) professional relationship (2) clinical impact (3) individual's preferences and (4) feasibility. The tool could also serve as a framework for guidelines on the topic.

Original language	English
Pages (from-to)	22-26
Number of pages	5
Journal	European Journal of Cancer
Volume	186
DOIs	https://doi.org/10.1016/j.ejca.2023.03.004
Publication status	Published - Jun 2023

Bibliographical note

Funding Information:
This study was performed as a part of the “Technology Assessment of Next Generation Sequencing in Personalized Oncology ( TANGO )” project, funded by ZonMW , (The Netherlands Organisation for Health Research and Development) #846001002 .

Publisher Copyright:
© 2023 The Authors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.ejca.2023.03.004Licence: CC BY-NC

Duty to recontact in genomic cancer careFinal published version, 535 KBLicence: CC BY-NC

Cite this

@article{e963130debec462c860b84aed989cf93,

title = "Duty to recontact in genomic cancer care: A tool helping to assess the professional's responsibility",

abstract = "Tumour DNA and germline testing, based on DNA-wide sequencing analysis, are becoming more and more routine in clinical-oncology practice. A promising step in medicine, but at the same time leading to challenging ethicolegal questions. An important one is under what conditions individuals (patients and their relatives, research participants) should be recontacted with new information, even if many years have passed since the last contact. Based on legal- and ethical study, we developed a tool to help professionals to decide whether or not to recontact an individual in specific cases. It is based on four assessment criteria: (1) professional relationship (2) clinical impact (3) individual's preferences and (4) feasibility. The tool could also serve as a framework for guidelines on the topic.",

author = "Ploem, \{Martine C.\} and Giesbertz, \{Noor A.A.\} and Bredenoord, \{Annelien L.\} and Ret{\`e}l, \{Valesca P.\} and \{van Harten\}, \{Wim H.\}",

note = "Funding Information: This study was performed as a part of the “Technology Assessment of Next Generation Sequencing in Personalized Oncology ( TANGO )” project, funded by ZonMW , (The Netherlands Organisation for Health Research and Development) \#846001002 . Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = jun,

doi = "10.1016/j.ejca.2023.03.004",

language = "English",

volume = "186",

pages = "22--26",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Duty to recontact in genomic cancer care

T2 - A tool helping to assess the professional's responsibility

AU - Ploem, Martine C.

AU - Giesbertz, Noor A.A.

AU - Bredenoord, Annelien L.

AU - Retèl, Valesca P.

AU - van Harten, Wim H.

N1 - Funding Information: This study was performed as a part of the “Technology Assessment of Next Generation Sequencing in Personalized Oncology ( TANGO )” project, funded by ZonMW , (The Netherlands Organisation for Health Research and Development) #846001002 . Publisher Copyright: © 2023 The Authors

PY - 2023/6

Y1 - 2023/6

N2 - Tumour DNA and germline testing, based on DNA-wide sequencing analysis, are becoming more and more routine in clinical-oncology practice. A promising step in medicine, but at the same time leading to challenging ethicolegal questions. An important one is under what conditions individuals (patients and their relatives, research participants) should be recontacted with new information, even if many years have passed since the last contact. Based on legal- and ethical study, we developed a tool to help professionals to decide whether or not to recontact an individual in specific cases. It is based on four assessment criteria: (1) professional relationship (2) clinical impact (3) individual's preferences and (4) feasibility. The tool could also serve as a framework for guidelines on the topic.

AB - Tumour DNA and germline testing, based on DNA-wide sequencing analysis, are becoming more and more routine in clinical-oncology practice. A promising step in medicine, but at the same time leading to challenging ethicolegal questions. An important one is under what conditions individuals (patients and their relatives, research participants) should be recontacted with new information, even if many years have passed since the last contact. Based on legal- and ethical study, we developed a tool to help professionals to decide whether or not to recontact an individual in specific cases. It is based on four assessment criteria: (1) professional relationship (2) clinical impact (3) individual's preferences and (4) feasibility. The tool could also serve as a framework for guidelines on the topic.

UR - https://www.scopus.com/pages/publications/85151561017

U2 - 10.1016/j.ejca.2023.03.004

DO - 10.1016/j.ejca.2023.03.004

M3 - Article

C2 - 37028199

AN - SCOPUS:85151561017

SN - 0959-8049

VL - 186

SP - 22

EP - 26

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Duty to recontact in genomic cancer care: A tool helping to assess the professional's responsibility

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this